1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,150 | 1,170 | 18.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon | 520 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 10.08. | NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak | 10.718 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 30.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 9 | SEC Filings | ||
| 28.07. | NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial | 9.064 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 24.07. | NanoViricides announces $3.8M registered direct offering; shares down | 5 | Seeking Alpha | ||
| 24.07. | NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering | 1.390 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 22.07. | As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola | 8.762 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 17.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.07. | As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo | 641 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 08.07. | Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | 729 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a... ► Artikel lesen | |
| 06.07. | Noble Capital startet Coverage für NanoViricides mit "Outperform" | 1 | Investing.com Deutsch | ||
| 06.07. | Noble Capital initiates NanoViricides stock with Outperform rating | 3 | Investing.com | ||
| 06.07. | As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo | 584 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it... ► Artikel lesen | |
| 29.06. | NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher | 801 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 22.06. | NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo | 1.030 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical... ► Artikel lesen | |
| 15.06. | As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo | 1.117 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 08.06. | As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies | 842 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 26.05. | In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides | 888 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential... ► Artikel lesen | |
| 20.05. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | NanoViricides Announces Closing of ~$2 Million Registered Direct Offering | 861 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 18,600 | +1,09 % | Formycon steigert Umsatz deutlich und bestätigt Jahresprognose | Formycon hat im ersten Halbjahr 2026 den Umsatz nahezu verdreifacht und das operative Ergebnis deutlich verbessert. Der Biosimilar-Entwickler bestätigt seine Jahresprognose und meldet wichtige Fortschritte... ► Artikel lesen | |
| ONTO INNOVATION | 272,10 | -0,07 % | This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| VEECO INSTRUMENTS | 46,040 | +4,61 % | VEECO INSTRUMENTS INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| RIBER | 9,460 | 0,00 % | RIBER: FIRST-HALF 2026 BUSINESS ACTIVITY Business growth, resilient order book and continued rollout of ROSIE | FIRST-HALF 2026 BUSINESS ACTIVITYBusiness growth, resilient order book and continued rollout of ROSIE Bezons, July 22, 2026 - 8:00 am - RIBER, the global leader in molecular beam epitaxy (MBE) equipment... ► Artikel lesen | |
| NVE | 100,00 | +0,50 % | Dividendenbekanntmachungen (03.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR BF SPA IT0005187460 - 0,038 EUR CITIZENS & NORTHERN CORPORATION US1729221069 0... ► Artikel lesen | |
| GAUZY | 0,370 | +0,22 % | Gauzy Ltd. - 6-K, Report of foreign issuer | ||
| KOPIN | 4,460 | +2,13 % | Fabric.AI and Kopin Launch Joint Steering Committee Led by Kopin CEO Michael Murray as Neural I/o Industry Engagement Expands | ||
| NANOVEU | 0,050 | -1,98 % | XFRA Q2L: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| GOMSPACE | 1,066 | +1,72 % | GomSpace A/S: GomSpace Signs 24.4 MSEK Contract with Unseenlabs | Unseenlabs extends its existing cube satellites constellation.STOCKHOLM, July 1, 2026 /PRNewswire/ -- Today, GomSpace has signed an additional contract with Unseenlabs to deliver two new... ► Artikel lesen | |
| SOLESENCE | 0,860 | -2,91 % | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | |
| ACACIA RESEARCH | 3,940 | +2,07 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,366 | 0,00 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| LAMPETIA | 0,161 | 0,00 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| ZENTEK | 0,482 | 0,00 % | Zentek Ltd.: Zentek Files Provisional Patent Application for Absorption-Based EMI Shielding Coating Made from Albany Graphite | Guelph, Ontario--(Newsfile Corp. - August 17, 2026) - Zentek Ltd. (TSXV: ZEN) (NASDAQ: ZTEK) ("Zentek" or the "Company") has filed a provisional patent application with the United States Patent... ► Artikel lesen | |
| REGION GROUP | 1,376 | -2,20 % | Region Group FY26 FFO Rises 2.7% Y-o-Y |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 1,140 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.